Projects & Perspectives
Stories of Science, Creativity, and Commitment.
Validating the Science
Our NIH SBIR Phase I Grant
"In 2026, Elexis Group submitted a Phase I SBIR grant to the National Institutes of Health (NIH) to clinically validate The Elexis Method® as a topical system for cutaneous stress response modulation and androgen-driven skin resilience."
Phase I
2026-2027: Feasibility studies, in vitro validation, pilot human trial.
Phase II
2027-2029: Large-scale clinical trial, regulatory preparation.
Phase IIB Bridge
2029-2031: Commercialization, manufacturing scale-up, product launch.
Why This Matters: This grant represents a critical validation of our scientific platform. It positions Elexis Group as a medically credible innovator, distinguishes us from conventional beauty brands, and lays the groundwork for Phase II funding and eventual FDA drug classification.
The Elexis Method®
Research & Development
The Elexis Method® emerged from a singular insight: that the body's adaptive intelligence could be supported, not overridden. Our founder's self-experimentation—documenting the release of terminal chin hairs, the reduction of heart palpitations, and the restoration of skin clarity—became the foundation of our scientific approach.
Key Research Milestones
- 2021-2024: Founder's N-of-1 self-experimentation with adaptogen-rich formulations.
- 2025: Product formulation finalized with 40+ testers across general skincare, hormonal acne, hirsutism, menopause use cases.
- 2026: Provisional patent filed for the novel combination for topical DHT-targeting formula.
- 2026: NIH SBIR Phase I grant submitted.